Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections.
Open Forum Infect Dis
; 7(3): ofaa051, 2020 Mar.
Article
en En
| MEDLINE
| ID: mdl-32161775
ABSTRACT
Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.
Texto completo:
1
Bases de datos:
MEDLINE
Idioma:
En
Revista:
Open Forum Infect Dis
Año:
2020
Tipo del documento:
Article
País de afiliación:
Estados Unidos